Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Medicine Matters diabetes

Dr. Fernando’s recommendation

I recommend coming to a mutual agreement with the patient to switch from gliclazide to liraglutide od in view of its cardioprotective properties, but also to aid weight loss and minimize the risk of future hypoglycemia. While an SGLT2 inhibitor could be considered it should not be initiated due to this patient’s impaired renal function (all currently available SGLT2 inhibitors can only be initiated if eGFR is greater than 60 mL/min per 1.73 m2 according to SIGN 154 [4]).

Prescribing notes: Empagliflozin and canagliflozin can only be initiated if eGFR is over 60 mL/min per 1.73 m2. However, if eGFR subsequently falls below 60 mL/min per 1.73 m2, empagliflozin can be continued at 10 mg od and canagliflozin at 100 mg od. However, both empagliflozin and canagliflozin must be stopped if eGFR drops below 45 mL/min per 1.73 m2 [1,2].
eGFR=estimated glomerular filtration rate; HbA1c=glycated hemoglobin; od=once daily; SGLT2=sodium-glucose cotransporter 2